1. The Future Costs, Risks and Rewards of Drug Development

   • Joseph Cook
   • Graeme Hunter
   • John A. Vernon

   Current Opinion 17 September 2012 Pages: 355 - 363

   

2. The Cost and Impact of Health Conditions on Presenteeism to Employers

   • Alyssa B. Schultz
   • Chin-Yu Chen
   • Dee W. Edington

   Review Article 17 September 2012 Pages: 365 - 378

   

3. Costing Infectious Disease Outbreaks for Economic Evaluation

   • Jeroen Luyten
   • Philippe Beutels

   Review Article 17 September 2012 Pages: 379 - 389

   

4. The Cost of Dementia in Europe

   • Linus Jönsson
   • Anders Wimo

   Review Article 17 September 2012 Pages: 391 - 403

   

5. Utility Assessment in Patients with Mental Disorders

   • Hans-Helmut König
   • Oliver H. Günther
   • Christiane Roick

   Original Research Article 17 September 2012 Pages: 405 - 419

   

6. Outcomes Associated with Initial versus Later Vancomycin Use in Patients with Complicated Skin and Skin-Structure Infections

   • Kamal M. F. Itani
   • Kasem S. Akhras
   • Sanjay Merchant

   Original Research Article 17 September 2012 Pages: 421 - 430

   

7. Pharmaceutical Risk-Sharing Agreements

   • Afschin Gandjour

   Correspondence 17 September 2012 Pages: 431 - 432

8. Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium

   • Irina Cleemput
   • Nancy Thiry

   Correspondence 17 September 2012 Pages: 433 - 433

9. The Author’s Reply

   • Lieven Annemans

   Correspondence 17 September 2012 Pages: 433 - 434

10. Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs

    • Brian Godman
    • Ulrich Schwabe
    • Björn Wettermark

    Research Letter 17 September 2012 Pages: 435 - 438